# Open Orphan successfully completes PrEP Biopharm Toxicology study for respiratory ‘viral mimic’

- Link: https://www.directorstalkinterviews.com/open-orphan-successfully-completes-prep-biopharm-toxicology-study-for-respiratory-viral-mimic/412949891
- Published: 2020-12-23T07:09:52+00:00
- Author: Giles

**Open Orphan plc** ([LON:ORPH](https://www.directorstalkinterviews.com/company/open-orphan-plc/orph.l)),
a rapidly growing specialist pharmaceutical services CRO which is the world leader
in the testing of vaccines and antivirals using human challenge clinical trials,
has announced that drug development company PrEP Biopharm Limited, which is 62.6%
owned by Open Orphan, has successfully completed a 12-week toxicology study for 
its novel pan-viral prophylactic asset, PrEP-001.

The animal model study provides safety data needed to move PrEP-001 into longer 
duration dosing in clinical studies. PrEP Biopharm intends to move forward with 
a real-world, field trial intended to validate the efficacy of its PrEP-001 against
all circulating respiratory viruses, including COVID-19, influenza and the common
cold.

PrEP-001 is neither a vaccine nor an antiviral. Rather, it is a synthetic RNA ‘viral
mimic’ that stimulates the body’s pan-viral innate immune response locally in the
upper respiratory tract. Administered via a once daily nasal spray it leverages 
the innate immune system to create an antiviral environment to stop invading respiratory
viruses. As such, it is possible that PrEP-001 could be used as a stand-alone pan-
viral prophylaxis or as an adjuvant for live and inactivated or peptide intranasal
vaccines targeting specific respiratory viruses. Previous studies in animals have
demonstrated that intranasal administration of poly IC shortly after vaccination
with live attenuated, inactivated and haemagglutinin antigen preparations of influenza
virus enhanced respiratory dendritic cell function, CD8 T cell formation, and production
of neutralising antibodies.

When Open Orphan acquired hVIVO in January 2020, in addition to acquiring the world
leader in the testing of vaccines and antivirals using human challenge studies, 
hVIVO also came with a number of non-core assets including a 62.6% stake in PrEP
Biopharm. The previous hVIVO Board had used shareholders’ funds to invest in these
non-core assets. The Open Orphan Board and management team are primarily focussed
upon cementing its position as a unique CRO and is committed to directing all resources
to further improving the quality of earnings in both Venn Life Sciences and hVIVO
and with shareholder funds only being used to support the profitable CRO services
business. In recent months, Open Orphan has made it clear that it intends to monetise
these non-core assets, however, as part of monetising these non-core assets, Open
Orphan does not intend to invest any of the Open Orphan shareholders’ funds but 
will continue to work with the PrEP Biopharm management team to secure other sources
of funding outside of the Open Orphan group while maximising the potential of these
non-core assets.

**Cathal Friel, Executive Chairman of Open Orphan, said: **“It is very encouraging
to note PrEP Biopharm’s progress towards the ultimate goal of validating the effectiveness
of their one dosage nasal spray for key respiratory viruses like COVID-19, flu and
the common cold. This safety data allows them to move into Phase 2b field studies
and we are very excited that PrEP-001 could play a meaningful role in the current
COVID-19 pandemic and future potential pandemics caused by new respiratory viruses.”

> **Cathal told DirectorsTalk:** “PrEP Biopharm, a company owned 62.6% by Open Orphan,
> has successfully completed a 12-week toxicology study for its novel pan-viral 
> prophylactic asset, PrEP-001. This study provided key safety data and this asset
> can now continue to a Phase IIb field trial to validate its efficacy against all
> circulating respiratory viruses, including COVID-19, influenza and the common 
> cold. PrEP-001, as a single dose nasal spray, removes any requirement for highly
> trained medical staff to administer same. 
> When we acquired hVIVO in January 2020, it had a number of non-core assets including
> a 62.6% stake in PrEP Biopharm. We are now actively in the process of monetizing
> this asset, we are looking to either sell PrEP as a going concern or reversing
> it into a larger publicly listed company and receiving equity for same. PrEP-001
> is quite an exciting product given its pan-viral method of action, it works by
> stimulating the host’s innate immune response and protects against all respiratory
> viruses such as COVID-19, Influenza or the common cold. Most respiratory virus
> replication begins in the nasal passages and as this product is administered using
> a nasal spray, PrEP-001 pre-activates the body’s natural immune defences to prevent
> viral replication where it begins.”

Share on:
